{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:38:37Z","timestamp":1791290317028,"version":"4.3.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure\/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg\/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg\/d with escalation to 1,000 mg\/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor\u2013A or \u2013B were found. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> In the dose range of 600 to 1,000 mg\/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.16.9235","type":"journal-article","created":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T22:23:56Z","timestamp":1222727036000},"page":"4659-4665","source":"Crossref","is-referenced-by-count":193,"title":["Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study"],"prefix":"10.1200","volume":"26","author":[{"given":"Eric","family":"Raymond","sequence":"first","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba A.","family":"Brandes","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dittrich","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fumoleau","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Coudert","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.J.","family":"Clement","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Frenay","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Rampling","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan M.","family":"Kros","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Lacombe","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"van den Bent","sequence":"additional","affiliation":[{"name":"From the Service Inter Hospitalier de Canc\u00e9rologie, Beaujon University Hospital, Clichy; Centre Georges-Fran\u00e7ois Leclerc, Dijon; Antoine Lacassagne Center, Nice, France; Bellaria and Maggiore Hospitals, Azienda Unit\u00e0 Sanitaria Locale of Bologna, Bologna, Italy; Applied Cancer Research-Institute for Translational Research; Ludwig Boltzmann-Institute for Applied Cancer Reearch; Kaiser Franz Josef Spital, Vienna, Austria; Leuven Cancer Institute, University Hospital Leuven, Leuven; European Organisation for..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Hermanson M, Funa K, Koopman J, et al: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor \u03b1 receptor expression in human gliomas. Cancer Res 56:164,1996-171,"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910600206"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/59.6.495"},{"key":"R4","unstructured":"Chin LS, Murray SF, Zitnay KM, et al: K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction. Clin Cancer Res 3:771,1997-776,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041580221"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199802000-00080"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Robinson SW, Cohen M, Prayson R, et al: Constitutive expression of growth-related oncogene and it receptor in oligodendrogliomas. Neurosurgery 48:864,2001-874,","DOI":"10.1227\/00006123-200104000-00035"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10361"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/303390a0"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00075-6"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1101\/gad.903001"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00836-5"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209497"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.0717"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.3.3763"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2572"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf121"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00070-9"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg491"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0773"},{"key":"R24","unstructured":"Reardon D, Friedman A, Herndon JE, et al: Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Neuro Oncol 6:381,2004,  (abstr TA-47)"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi317"},{"key":"R26","unstructured":"Dresemann G, Rosenthal M, H\u00f6ffken K, et al: Imatinib plus hydroxyurea versus hydroxyurea in progressive glioblastoma (GBM): An international open label randomised phase III study (AMBROSIA study). Neuro Oncol 9:519,2007,  (abstr MA-17)"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-031"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.05.003"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Razis E, Selviaridis P, Fletcher J, et al: Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib. J Clin Oncol 25:80s,2007,  (suppl; abstr 2023)","DOI":"10.1200\/jco.2007.25.18_suppl.2023"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.11.021"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.16.9235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:21:55Z","timestamp":1653510115000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.16.9235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":32,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2008,10,1]]}},"alternative-id":["10.1200\/JCO.2008.16.9235"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.16.9235","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}